Schepens Eye Research Institute Report issue

Academic/Hospital Phase 2 Phase 4

Organization Overview

First Clinical Trial
2003
NCT00406991
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Schepens Eye Research Institute

Active Ingredients

Drugs in Phase 4 Trials (1)

hyaluronic acid (1 trial)

Drugs in Phase 2 Trials (2)

acetylsalicylic acid (aspirin) (1 trial)

clopidogrel (plavix) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetic Retinopathy (Phase 2)

Dry Eye Syndromes (Phase 4)

Keratoconjunctivitis Sicca (Phase 4)

Retinal Diseases (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 3